ストックスクリーナーアプリを入手
3.06
0.66%
0.02
アフターアワーズ：
3.07
0.010
+0.33%
前日終値:
$3.04
開ける：
$3.05
24時間の取引高:
2.86M
Relative Volume:
0.65
時価総額：
$595.22M
収益：
$36,000
当期純損益:
$-91.08M
株価収益率:
-3.2637
EPS:
-0.9376
ネットキャッシュフロー:
$-71.67M
1週間 パフォーマンス:
-5.85%
1か月 パフォーマンス:
-4.38%
6か月 パフォーマンス:
-7.55%
1年 パフォーマンス:
-21.94%
1日の値動き範囲:
$3.00
$3.11
1週間の範囲:
$2.98
$3.425
52週間の値動き範囲:
$2.56
$6.4399
Altimmune Inc Stock (ALT) Company Profile
Compare ALT vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.06 | 595.22M | 36,000 | -91.08M | -71.67M | -0.9376 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-24 | アップグレード | Goldman | Sell → Neutral |
| 2026-03-18 | 開始されました | Truist | Buy |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2025-07-10 | 再開されました | Goldman | Sell |
| 2025-02-28 | 開始されました | William Blair | Mkt Perform |
| 2025-01-08 | 開始されました | Stifel | Buy |
| 2024-11-12 | 開始されました | UBS | Buy |
| 2024-04-29 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-01-24 | 開始されました | Goldman | Neutral |
| 2023-03-22 | ダウングレード | Goldman | Buy → Neutral |
| 2022-12-01 | 開始されました | Goldman | Buy |
| 2021-12-29 | 再開されました | Jefferies | Buy |
| 2021-06-02 | 開始されました | H.C. Wainwright | Buy |
| 2021-02-11 | 開始されました | Guggenheim | Buy |
| 2020-12-14 | 開始されました | Jefferies | Buy |
| 2020-11-12 | 繰り返されました | B. Riley Securities | Buy |
| 2020-09-25 | 開始されました | B. Riley FBR | Buy |
| 2020-08-14 | 開始されました | Evercore ISI | Outperform |
| 2020-07-31 | 開始されました | Piper Sandler | Overweight |
| 2020-07-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-02-24 | 再開されました | ROTH Capital | Buy |
| 2019-07-19 | 開始されました | ROTH Capital | Buy |
| 2017-10-09 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Altimmune Inc (ALT) 最新ニュース
Altimmune Stock Price Forecast. Should You Buy ALT? - StockInvest.us
ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff - Stocktwits
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Evercore Maintains Altimmune(ALT.US) With Buy Rating, Cuts Target Price to $17 - Moomoo
Altimmune’s Phase 3 MASH Trial Puts Pemvidutide in the Spotlight for Investors - TipRanks
ALT Maintained by Evercore ISI Group -- Price Target Lowered to $17 - GuruFocus
Altimmune to Participate in Stifel Cardiometabolic Forum - The Manila Times
Altimmune, Inc. (ALT) Stock Price, News, Quote & History - Yahoo! Finance Canada
Altimmune Inc. (ALT) Edges Higher to $3.27 as Shares Hold Mid-RangeETF Outflow Streak - siam.in
Altimmune, Inc. (ALT) Stock Analysis: Biotech's Potential 431.55% Upside Draws Investor Attention - DirectorsTalk Interviews
Altimmune (ALT) exec gains stock as 24,000 RSUs vest - Stock Titan
Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10% - Stocktwits
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report? - Yahoo Finance
Altimmune at Wells Fargo healthcare conference: pemvidutide push By Investing.com - Investing.com Canada
Altimmune’s (ALT) Three Liver Trials Move Forward At Once - Yahoo Finance
Altimmune Inc. (ALT) Peer Comparison – Compare with Others - Value Research
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference - marketscreener.com
Altimmune (ALT) Trading: Closes 5.42% Higher at $3.11 in the Current Update; Price Setup: the Supplied Trading Band Runs From $2.95 to $3.27 in Latest TradingValue Area Low - careplusvn.com
Altimmune (NASDAQ:ALT) Trading Up 9.2%Should You Buy? - MarketBeat
ALT Stock Drops Pre-Market On Dilution Fears – Retail Calls It A ‘Horror Story’ - Stocktwits
Altimmune Inc (ALT) News, Articles, Events & Latest Updates - Stocktwits
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger? - Yahoo Finance
Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus - Yahoo Finance
HC Wainwright Estimates Altimmune's Q3 Earnings (NASDAQ:ALT) - MarketBeat
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune (ALT) Rises 2.08% to $2.94 as Shares Hold Above Key SupportActive ETF Flow - Vinanet
Altimmune Inc (ALT) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits
9 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Altimmune (ALT) Q2 2026 Earnings Call: PERFORMA Starts, Cash Reaches $519M - TradingKey
ALT|Altimmune Inc|Price:3.110|Chg%:+0.160 - TradingKey
Altimmune (ALT) President and CEO Jerome Durso Buys 15,000 Shares - GuruFocus
Altimmune CEO Jerome Benedict Durso Buys 15,000 Shares at $2.95 Each - Kalkine Media
Altimmune (ALT) CEO Jerome Durso purchases 15,000 shares at $2.95 each - Stock Titan
Altimmune: Pemvidutide Performs, But A Long Wait Ahead (NASDAQ:ALT) - Seeking Alpha
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus - The Globe and Mail
Barclays Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Altimmune Inc RECLAIM Phase 2 Trial in AUD Topline Results Conference Call Transcript - GuruFocus
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Altimmune (NASDAQ:ALT): What Does the Latest Update Mean for Trial Execution? - kalkinemedia.com
Altimmune Inc Phase 2b Topline 48-Week Data Conference Call Transcript - GuruFocus
Dimensional Fund Advisors LP Raises Stake in Altimmune, Inc. $ALT - MarketBeat
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... - Yahoo Finance Australia
Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancin - GuruFocus
Altimmune Reports Q2 2026 Financial Results and SEC Filing Highlighting Increased Assets and Equity Raise - kalkinemedia.com
Altimmune, Inc. Q2 2026: Revenue $0 EPS $(0.12) — 10-Q Summary - TradingView
Altimmune (ALT) grows cash reserves above $518M while advancing Phase 3 MASH trial - Stock Titan
Altimmune (ALT) Advances Clinical Trials Amidst High Price-to-Sa - GuruFocus
Altimmune Releases Q2 2026 Financial Results - AlphaStreet
William Blair Maintains Altimmune(ALT.US) With Hold Rating - Moomoo
Altimmune Inc (ALT) 財務データ
収益
当期純利益
現金流量
EPS
3.06%
2.55%
大文字化:
|
ボリューム (24 時間):